Our Newsroom

At Accord BioPharma, weโ€™re never content with the status quo.

Accord BioPharma Announces New Executive Leadership in Commercialization and Marketing

Mar 9, 2022, 18:18 ET

DURHAM, N.C., March 9, 2022 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today the hire of several key members of its leadership team: George Esgro Jr. as Senior Vice President of Commercial Operations; Kayla Williams as Executive Director of U.S. Portfolio Strategy and Commercial Development; Nuvan Dassanaike as Senior Vice President of Digital and Marketing Strategy & Operations; and Paul Purdy as Vice President and Head of Market Access.

"I am pleased to welcome George, Kayla, Nuvan, and Paul to the team. Together, these team members offer a unique blend of seasoned experience with fresh, entrepreneurial thinking essential to driving innovative, patient-centric solutions in the U.S. pharmaceutical market," said Chrys Kokino, President of U.S. BioPharma at Accord BioPharma. "As we seek to improve treatment adoption, adherence, and outcomes, I am confident that with this team in place, we are ready to provide great value to our stakeholders and patients."

George Esgro Jr., a seasoned pharmaceutical industry veteran with experience across various companies including GSK, Amgen, and Roche, joins Accord BioPharma from Ashfield Healthcare, where he served as President of Global Business Development. Prior to Ashfield Healthcare, George worked at Quintiles (now IQVIA) in various commercial roles, where he provided strategy and project oversight as Vice President, General Manager of Commercial Operations, and Strategic Accounts for Commercial North America.  

With more than 12 years in the pharmaceutical industry, Kayla Williams joins Accord BioPharma from Mylan, where she developed international commercialization strategies for biosimilars in oncology, immunology, and endocrinology. Kayla has held various commercial roles with responsibilities including insights & analytics, launch management, forecasting, strategic planning, and portfolio analysis.โ€ฏHer skill set spans multiple verticals in commercialization, including performing in-depth product assessments, formulating pricing strategies, coding and reimbursement, U.S. commercial channel strategies, and developing strategies across market segments. 

Nuvan Augustin Dassanaike brings more than 19 years' experience in marketing and digital transformation at global life sciences organizations including Mylan, GSK, ZT Bio Pharma (GNC), and Abbott. Through his digital marketing, innovation, and customer experience leadership, Nuvan has contributed to gains in revenue streams and capturing market share in therapeutic areas such as oncology, respiratory, CNS, and gastroenterology. 

During his 30 years of market access experience at companies including GSK, Amgen, and Agios, Paul Purdy has led teams for both market access and sales. He has launched more than 18 products across therapeutic areas such as oncology, endocrinology, rheumatology, neurology, and rare diseases. At Accord BioPharma, Paul will lead a team focused on obtaining access across the payer, distributor and GPO customer channels. 

"This leadership team is one built from trusted professional relationships, shared expertise, and a desire to evolve existing treatment options to improve the entire experience for patients, caregivers, healthcare practitioners, and others involved in the healthcare journey," said Kokino.  

About Accord BioPharma 

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patient's perspective and develop high-quality therapies that impact their lives. The founders of Accord BioPharma have dedicated their time, passion, and resources to focusing on specialty care and treatments, proactively developing better ways of working, and delivering enhanced therapies. For more information, Visit AccordBioPharma.com

Contact:

Nuvan Dassanaike

Senior Vice President Digital and Marketing Strategy & Operations

Cell: (412) 553-9955

SOURCE Accord BioPharma

Latest Press Releases

This year's President's Club winners didn't follow the standard โ€” they set it.ย  A heartfelt congratulations to this team. Your dedication inspire...

Read more

Weโ€™re proud to announce that the US FDA has approved our second pegfilgrastim biosimilar in our portfolio,...

Read more

June is Men's Health Month, a reminder that early screening and proactive care can change outcomes.ย  ย  For men living with advanced prostate cancer,...

Read more

For us, Beyond Biology means building a workplace where every person feels seen, heard, and valued.ย  ย  This June, we're celebrating the communities ...

Read more

We recognize the millions of Americans who are living beyond or with a cancer diagnosis, and the caregivers, clinicians, and communities who stand bes...

Read more

Every treatment journey relies on support that isnโ€™t always visible. On World Blood Donor Day, we recognize the voluntary blood donors whose contri...

Read more

Chrys Kokino, North America President,โ€ฏcame to Accord five years agoโ€ฏwith a simple question - why can't more patients...

Read more

As A S C O26 comes to a close, one thing is clear: Expanding access to high-quality cancer care has never been more urgent. Accord is advan...

Read more

We're in Chicago. The Accord team is on the ground at A S C O26, ready to connect with the oncology community. Come hear what weโ€™ve been ...

Read more

Read more

Oncology nurses are on the front lines of patient care โ€” managing complex treatment regimens, navigating access challenges, and advocating for their...

Read more

What does it mean to go "beyond biology"? It means we look beyond the molecule โ€” at administration, at access, at the full experience of treatment f...

Read more

From oncology supportive care to advanced prostate cancer, biosimilar and specialty pharmaceutical innovation is expanding across disease states โ€” i...

Read more

This World I B D Day, we're thinking about the millions of people navigating life with Crohn's disease and ulcerative colitis โ€” and the cli...

Read more

IMULDOSAยฎ \(ustekinumab-srlf\), our STELARAยฎ \(ustekinumab\), biosimilar, is now preferred under Cigna Healthcare commercial plans, effective April ...

Read more

Connect With Us